Diagnostic Performance of Serum AKR1B10 in Early‐Stage and AFP ‐Negative Hepatocellular Carcinoma: A Multicentre Study
Liver International · 2026
DOI: 10.1111/liv.70732 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Zhe Cao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Engineering Technology Research Center of Veterinary Drugs, Hunan Agricultural University, Changsha, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor, Aldo-Keto Reductase Family 1 member B10. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province, Health Commission of Hunan Province.
Abstract (Originalsprache)
Objective
Aldo‐keto reductase 1B10 (AKR1B10) is overexpressed in hepatocellular carcinoma (HCC). This study aimed to evaluate its diagnostic efficacy for early and alpha‐fetoprotein (AFP)‐negative HCC, and its potential role in assessing radical resection and early recurrence.
Methods
A large‐scale multicentre clinical study enrolled 1 352 subjects from three medical centres, including HCC, benign liver diseases, and non‐hepatocyte cancers. Serum samples were collected for AKR1B10 and AFP testing, and clinical and imaging data were collected for analysis.
Results
Serum AKR1B10 markedly increased in HCC patients to 1419.51 ± 89.09 pg/mL, compared to 177.96 ± 9.78 pg/mL in healthy controls. Receiver operating characteristic (ROC) curve analysis showed that for HCC diagnosis, AKR1B10 had an Area under the curve (AUC) of 0.866, sensitivity of 73.10%, and specificity of 95.24%, compared to AFP with 0.750, 64.27%, and 82.14%, respectively. In early HCC, AKR1B10 yielded an AUC of 0.800, a sensitivity of 65.8%, and a specificity of 91.67%, better than AFP (0.717, 59.83%, and 88.1%, respectively). AKR1B10 was positive in 69.27% of AFP‐negative HCC cases and showed an AUC of 0.852, a sensitivity of 72.2%, and a specificity of 90.48%. In patients with HCC undergoing curative resection, serum AKR1B10 levels declined to normal within 3–5 days. At 1–3 months after surgery, serum AKR1B10 had a concordance of 94.41% with imaging data, compared to 70.63% for AFP.
Conclusion
AKR1B10 is a useful serum marker for the diagnosis of early and AFP‐negative HCC and shows potential in assessing curative resection and early recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan Engineering Technology Research Center of Veterinary Drugs, Hunan Agricultural University, Changsha, China.
- Hunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University…
- The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
- Hunan Light of Life Biotechnology Co., Ltd., Hunan Province, China.
- Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
- Department of Hepatopancreatobiliary Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province
- Health Commission of Hunan Province
- Natural Science Foundation of Hunan Province
Zitieren
APA
Cao, Z., Xie, M., Ye, X., Wu, B., Wang, H., Chen, G., Cao, D., Wang, B., Zeng, X., & Sun, Z. (2026). Diagnostic Performance of Serum AKR1B10 in Early‐Stage and AFP ‐Negative Hepatocellular Carcinoma: A Multicentre Study. Liver International. https://doi.org/10.1111/liv.70732
Vancouver
Cao Z, Xie M, Ye X, Wu B, Wang H, Chen G, et al. Diagnostic Performance of Serum AKR1B10 in Early‐Stage and AFP ‐Negative Hepatocellular Carcinoma: A Multicentre Study. Liver International. 2026. doi:10.1111/liv.70732
BibTeX
@article{Cao2026,
author = {Cao, Zhe and Xie, Ming and Ye, Xu and Wu, Bin and Wang, Huiqing and Chen, Guodong and Cao, Deliang and Wang, Boqing and Zeng, Xi and Sun, Zhiliang},
title = {Diagnostic Performance of Serum AKR1B10 in Early‐Stage and AFP ‐Negative Hepatocellular Carcinoma: A Multicentre Study},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70732}
}
EUVIMED